{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:37:50Z","timestamp":1783532270995,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,4,11]],"date-time":"2008-04-11T00:00:00Z","timestamp":1207872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Currently, there is clear evidence that apoptosis plays an important role in the development and progression of tumors. One of the best characterized apoptosis triggering systems is the CD95\/Fas\/APO-1 pathway; previous reports have demonstrated high levels of soluble CD95 (sCD95) in serum of patients with some types of cancer. Cervical cancer is the second most common cancer among women worldwide. As a first step in an attempt to design a minimally invasive test to predict the risk of developing cervical cancer in patients with precancerous lesions, we used a simple assay based on the capacity of human serum to induce apoptosis in Jurkat cells. We evaluated the relationship between sCD95 levels and the ability to induce apoptosis in Jurkat cells in cervical cancer patients and controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Jurkat cells were exposed to serum from 63 women (20 healthy volunteers, 21 with cervical intraepithelial neoplasia grade I [CIN 1] and 22 with cervical-uterine carcinoma). The apoptotic rate was measured by flow cytometry using Annexin-V-Fluos and Propidium Iodide as markers. Serum levels of sCD95 and soluble CD95 ligand (sCD95L) were measured by ELISA kits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that serum from almost all healthy women induced apoptosis in Jurkat cells, while only fifty percent of the sera from women with CIN 1 induced cell death in Jurkat cells. Interestingly, only one serum sample from a patient with cervical-uterine cancer was able to induce apoptosis, the rest of the sera protected Jurkat cells from this killing. We were able to demonstrate that elimination of Jurkat cells was mediated by the CD95\/Fas\/Apo-1 apoptotic pathway. Furthermore, the serum levels of sCD95 measured by ELISA were significantly higher in women with cervical cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results demonstrate that there is a strong correlation between low levels of sCD95 in serum of normal women and higher apoptosis induction in Jurkat cells. We suggest that an analysis of the apoptotic rate induced by serum in Jurkat cells and the levels of sCD95 in serum could be helpful during the prognosis and treatment of women detected with precancerous lesions or cervical cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2407-8-99","type":"journal-article","created":{"date-parts":[[2008,4,11]],"date-time":"2008-04-11T18:14:33Z","timestamp":1207937673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer"],"prefix":"10.1186","volume":"8","author":[{"given":"Adriana","family":"Aguilar-Lemarroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E","family":"Romero-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Olimon-Andalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Hernandez-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Lerma-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo C","family":"Ortiz-Lazareno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Morgan-Villela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"del Toro-Arreola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Bravo-Cuellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F","family":"Jave-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,11]]},"reference":[{"key":"1037_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016\/S0092-8674(00)81683-9.","journal-title":"Cell"},{"key":"1037_CR2","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1038\/sj.onc.1207558","volume":"23","author":"KM Debatin","year":"2004","unstructured":"Debatin KM, Krammer PH: Death receptors in chemotherapy and cancer. Oncogene. 2004, 23: 2950-2966. 10.1038\/sj.onc.1207558.","journal-title":"Oncogene"},{"key":"1037_CR3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1196\/annals.1322.016","volume":"1028","author":"S Fulda","year":"2004","unstructured":"Fulda S, Debatin KM: Apoptosis signaling in tumor therapy. Ann N Y Acad Sci. 2004, 1028: 150-156. 10.1196\/annals.1322.016.","journal-title":"Ann N Y Acad Sci"},{"key":"1037_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1023\/B:CANC.0000031774.32572.df","volume":"23","author":"L Malaguarnera","year":"2004","unstructured":"Malaguarnera L: Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev. 2004, 23: 367-387. 10.1023\/B:CANC.0000031774.32572.df.","journal-title":"Cancer Metastasis Rev"},{"key":"1037_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2174\/1566524033479483","volume":"3","author":"JL Townson","year":"2003","unstructured":"Townson JL, Naumov GN, Chambers AF: The role of apoptosis in tumor progression and metastasis. Curr Mol Med. 2003, 3: 631-642. 10.2174\/1566524033479483.","journal-title":"Curr Mol Med"},{"key":"1037_CR6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1189\/jlb.71.6.907","volume":"71","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH: Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002, 71: 907-920.","journal-title":"J Leukoc Biol"},{"key":"1037_CR7","first-page":"1413","volume":"22","author":"AA Lettini","year":"2007","unstructured":"Lettini AA, Guidoboni M, Fonsatti E, Anzalone L, Cortini E, Maio M: Epigenetic remodelling of DNA in cancer. Histol Histopathol. 2007, 22: 1413-1424.","journal-title":"Histol Histopathol"},{"key":"1037_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1006\/scbi.2001.0405","volume":"12","author":"LE French","year":"2002","unstructured":"French LE, Tschopp J: Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol. 2002, 12: 51-55. 10.1006\/scbi.2001.0405.","journal-title":"Semin Cancer Biol"},{"key":"1037_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1242\/jcs.01610","volume":"118","author":"I Lavrik","year":"2005","unstructured":"Lavrik I, Golks A, Krammer PH: Death receptor signaling. J Cell Sci. 2005, 118: 265-267. 10.1242\/jcs.01610.","journal-title":"J Cell Sci"},{"key":"1037_CR10","first-page":"1","volume":"9","author":"SC Fas","year":"2006","unstructured":"Fas SC, Fritzsching B, Suri-Payer E, Krammer PH: Death receptor signaling and its function in the immune system. Curr Dir Autoimmun. 2006, 9: 1-17.","journal-title":"Curr Dir Autoimmun"},{"key":"1037_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.genet.33.1.29","volume":"33","author":"S Nagata","year":"1999","unstructured":"Nagata S: Fas ligand-induced apoptosis. Annu Rev Genet. 1999, 33: 29-55. 10.1146\/annurev.genet.33.1.29.","journal-title":"Annu Rev Genet"},{"key":"1037_CR12","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1016\/S0021-9258(19)50076-X","volume":"267","author":"A Oehm","year":"1992","unstructured":"Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, .: Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor\/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992, 267: 10709-10715.","journal-title":"J Biol Chem"},{"key":"1037_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0092-8674(91)90614-5","volume":"66","author":"N Itoh","year":"1991","unstructured":"Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991, 66: 233-243. 10.1016\/0092-8674(91)90614-5.","journal-title":"Cell"},{"key":"1037_CR14","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1074\/jbc.271.28.16443","volume":"271","author":"AM Chinnaiyan","year":"1996","unstructured":"Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, Dixit VM: FADD\/MORT1 is a common mediator of CD95 (Fas\/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 1996, 271: 4961-4965. 10.1074\/jbc.271.9.4961.","journal-title":"J Biol Chem"},{"key":"1037_CR15","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1002\/j.1460-2075.1995.tb00245.x","volume":"14","author":"FC Kischkel","year":"1995","unstructured":"Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME: Cytotoxicity-dependent APO-1 (Fas\/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995, 14: 5579-5588.","journal-title":"EMBO J"},{"key":"1037_CR16","doi-asserted-by":"publisher","first-page":"46639","DOI":"10.1074\/jbc.M105102200","volume":"276","author":"FC Kischkel","year":"2001","unstructured":"Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, Gazdar A, Blenis J, Arnott D, Ashkenazi A: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001, 276: 46639-46646. 10.1074\/jbc.M105102200.","journal-title":"J Biol Chem"},{"key":"1037_CR17","doi-asserted-by":"publisher","first-page":"d12","DOI":"10.2741\/A112","volume":"1","author":"I Cascino","year":"1996","unstructured":"Cascino I, Papoff G, Eramo A, Ruberti G: Soluble Fas\/Apo-1 splicing variants and apoptosis. Front Biosci. 1996, 1: d12-d18.","journal-title":"Front Biosci"},{"key":"1037_CR18","first-page":"3529","volume":"5","author":"T Ueno","year":"1999","unstructured":"Ueno T, Toi M, Tominaga T: Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res. 1999, 5: 3529-3533.","journal-title":"Clin Cancer Res"},{"key":"1037_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00268-002-6378-5","volume":"27","author":"SM Sheen-Chen","year":"2003","unstructured":"Sheen-Chen SM, Chen HS, Eng HL, Chen WJ: Circulating soluble Fas in patients with breast cancer. World J Surg. 2003, 27: 10-13. 10.1007\/s00268-002-6378-5.","journal-title":"World J Surg"},{"key":"1037_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0022-5347(01)62960-4","volume":"160","author":"Y Mizutani","year":"1998","unstructured":"Mizutani Y, Yoshida O, Bonavida B: Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol. 1998, 160: 571-576. 10.1016\/S0022-5347(01)62960-4.","journal-title":"J Urol"},{"key":"1037_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0090-4295(99)00379-9","volume":"55","author":"N Nonomura","year":"2000","unstructured":"Nonomura N, Nishimura K, Ono Y, Fukui T, Harada Y, Takaha N, Takahara S, Okuyama A: Soluble Fas in serum from patients with renal cell carcinoma. Urology. 2000, 55: 151-155. 10.1016\/S0090-4295(99)00379-9.","journal-title":"Urology"},{"key":"1037_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/BF02888075","volume":"21","author":"Z Peng","year":"2001","unstructured":"Peng Z, Tang H, Ling Y, Han G: Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma. J Tongji Med Univ. 2001, 21: 126-9, 148.","journal-title":"J Tongji Med Univ"},{"key":"1037_CR23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s10495-005-1018-9","volume":"10","author":"Z Kondera-Anasz","year":"2005","unstructured":"Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J: Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis. 2005, 10: 1143-1149. 10.1007\/s10495-005-1018-9.","journal-title":"Apoptosis"},{"key":"1037_CR24","first-page":"3576","volume":"6","author":"R Konno","year":"2000","unstructured":"Konno R, Takano T, Sato S, Yajima A: Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res. 2000, 6: 3576-3580.","journal-title":"Clin Cancer Res"},{"key":"1037_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nm0396-317","volume":"2","author":"M Tanaka","year":"1996","unstructured":"Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S: Fas ligand in human serum. Nat Med. 1996, 2: 317-322. 10.1038\/nm0396-317.","journal-title":"Nat Med"},{"key":"1037_CR26","first-page":"3870","volume":"56","author":"GP Midis","year":"1996","unstructured":"Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996, 56: 3870-3874.","journal-title":"Cancer Res"},{"key":"1037_CR27","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1046\/j.1365-2141.1998.01095.x","volume":"103","author":"K Kato","year":"1998","unstructured":"Kato K, Ohshima K, Ishihara S, Anzai K, Suzumiya J, Kikuchi M: Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Haematol. 1998, 103: 1164-1166. 10.1046\/j.1365-2141.1998.01095.x.","journal-title":"Br J Haematol"},{"key":"1037_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/hep.510300237","volume":"30","author":"M Nagao","year":"1999","unstructured":"Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H: The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?. Hepatology. 1999, 30: 413-421. 10.1002\/hep.510300237.","journal-title":"Hepatology"},{"key":"1037_CR29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.","journal-title":"CA Cancer J Clin"},{"key":"1037_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1155\/2007\/914823","volume":"23","author":"FX Bosch","year":"2007","unstructured":"Bosch FX, de SS: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 2007, 23: 213-227.","journal-title":"Dis Markers"},{"key":"1037_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc798","volume":"2","author":"HH zur","year":"2002","unstructured":"zur HH: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002, 2: 342-350. 10.1038\/nrc798.","journal-title":"Nat Rev Cancer"},{"key":"1037_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-19. 10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.","journal-title":"J Pathol"},{"key":"1037_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1155\/2007\/678793","volume":"23","author":"N Wentzensen","year":"2007","unstructured":"Wentzensen N, von Knebel DM: Biomarkers in cervical cancer screening. Dis Markers. 2007, 23: 315-330.","journal-title":"Dis Markers"},{"key":"1037_CR34","first-page":"73","volume":"119","author":"S Vinokurova","year":"2005","unstructured":"Vinokurova S, Wentzensen N, von Knebel DM: Analysis of p16INK4a and integrated HPV genomes as progression markers. Methods Mol Med. 2005, 119: 73-83.","journal-title":"Methods Mol Med"},{"key":"1037_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0028-2243(95)02303-A","volume":"65","author":"KJ Syrjanen","year":"1996","unstructured":"Syrjanen KJ: Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol. 1996, 65: 45-53. 10.1016\/0028-2243(95)02303-A.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1037_CR36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/91.3.252","volume":"91","author":"P Holowaty","year":"1999","unstructured":"Holowaty P, Miller AB, Rohan T, To T: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999, 91: 252-258. 10.1093\/jnci\/91.3.252.","journal-title":"J Natl Cancer Inst"},{"key":"1037_CR37","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/intimm\/7.11.1873","volume":"7","author":"ME Peter","year":"1995","unstructured":"Peter ME, Dhein J, Ehret A, Hellbardt S, Walczak H, Moldenhauer G, Krammer PH: APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int Immunol. 1995, 7: 1873-1877. 10.1093\/intimm\/7.11.1873.","journal-title":"Int Immunol"},{"key":"1037_CR38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1078-0432.1010.11.3","volume":"11","author":"JW Kim","year":"2005","unstructured":"Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL: Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005, 11: 1010-1020.","journal-title":"Clin Cancer Res"},{"key":"1037_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1074\/mcp.M200004-MCP200","volume":"1","author":"S Vejda","year":"2002","unstructured":"Vejda S, Posovszky C, Zelzer S, Peter B, Bayer E, Gelbmann D, Schulte-Hermann R, Gerner C: Plasma from cancer patients featuring a characteristic protein composition mediates protection against apoptosis. Mol Cell Proteomics. 2002, 1: 387-393. 10.1074\/mcp.M200004-MCP200.","journal-title":"Mol Cell Proteomics"},{"key":"1037_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/jcb.10382","volume":"88","author":"KV Gurova","year":"2003","unstructured":"Gurova KV, Gudkov AV: Paradoxical role of apoptosis in tumor progression. J Cell Biochem. 2003, 88: 128-137. 10.1002\/jcb.10382.","journal-title":"J Cell Biochem"},{"key":"1037_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0065-230X(06)97005-5","volume":"97C","author":"PH Krammer","year":"2007","unstructured":"Krammer PH, Kaminski M, Kiessling M, Gulow K: No Life Without Death. Adv Cancer Res. 2007, 97C: 111-138.","journal-title":"Adv Cancer Res"},{"key":"1037_CR42","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1126\/science.7510905","volume":"263","author":"J Cheng","year":"1994","unstructured":"Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994, 263: 1759-1762. 10.1126\/science.7510905.","journal-title":"Science"},{"key":"1037_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00008390-200010000-00008","volume":"10","author":"R Mouawad","year":"2000","unstructured":"Mouawad R, Khayat D, Soubrane C: Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res. 2000, 10: 461-467. 10.1097\/00008390-200010000-00008.","journal-title":"Melanoma Res"},{"key":"1037_CR44","first-page":"204","volume":"50","author":"E Jablonska","year":"2005","unstructured":"Jablonska E, Kiersnowska-Rogowska B, Rogowski F, Parfienczyk A, Puzewska W, Bukin M: Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL. Rocz Akad Med Bialymst. 2005, 50: 204-207.","journal-title":"Rocz Akad Med Bialymst"},{"key":"1037_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.clinbiochem.2006.09.003","volume":"40","author":"M Sahin","year":"2007","unstructured":"Sahin M, Aydintug O, Tunc SE, Tutkak H, Naziroglu M: Serum soluble Fas levels in patients with autoimmune rheumatic diseases. Clin Biochem. 2007, 40: 6-10. 10.1016\/j.clinbiochem.2006.09.003.","journal-title":"Clin Biochem"},{"key":"1037_CR46","first-page":"320","volume":"57","author":"K Kolomecki","year":"2006","unstructured":"Kolomecki K, Maciaszczyk P, Stepien H, Cywinski J, Cielecka J, Stepien T, Kuzdak K: [Evaluation of p53 and soluble Fas ligand (sFasL) serum level concentration as indicators of apoptosis in serum of patients with benign and malignant primary follicular thyroid tumors]. Endokrynol Pol. 2006, 57: 320-325.","journal-title":"Endokrynol Pol"},{"key":"1037_CR47","first-page":"103","volume":"9","author":"SC Lim","year":"2002","unstructured":"Lim SC: Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncol Rep. 2002, 9: 103-107.","journal-title":"Oncol Rep"},{"key":"1037_CR48","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1034\/j.1600-0609.2001.066005342.x","volume":"66","author":"LM Osorio","year":"2001","unstructured":"Osorio LM, guilar-Santelises M, De SA, Hachiya T, Mellstedt H, Jondal M: Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol. 2001, 66: 342-346. 10.1034\/j.1600-0609.2001.066005342.x.","journal-title":"Eur J Haematol"},{"key":"1037_CR49","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1002\/1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q","volume":"89","author":"S Tsutsumi","year":"2000","unstructured":"Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T: Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer. 2000, 89: 2560-2564. 10.1002\/1097-0142(20001215)89:12<2560::AID-CNCR7>3.0.CO;2-Q.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-99\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-99","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-99.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T21:26:58Z","timestamp":1708810018000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-8-99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-99","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,11]]},"assertion":[{"value":"27 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"99"}}